Financials

  • Market Capitalization 40.06 M
  • Employee 28
  • Founded 1996
  • CEO N/A
  • Website www.plustherapeutics.com
  • Headquarter Delaware, United States
  • FIGI BBG000C1Z086
  • Industry Biyoteknoloji
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
0.19
Fiyat/satışlar oranı
3.75

PLUS THERAPEUTICS, Inc. - Common Stock

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.

Haberler